Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, 513 Parnassus Avenue, Med Sci S357, San Francisco, CA 94143, USA.
Expert Rev Respir Med. 2011 Dec;5(6):809-21. doi: 10.1586/ers.11.76.
Until recently, relationships between evidence of colonization or infection by specific microbial species and the development, persistence or exacerbation of pulmonary disease have informed our opinions of airway microbiology. However, recent applications of culture-independent tools for microbiome profiling have revealed a more diverse microbiota than previously recognized in the airways of patients with chronic pulmonary disease. New evidence indicates that the composition of airway microbiota differs in states of health and disease and with severity of symptoms and that the microbiota, as a collective entity, may contribute to pathophysiologic processes associated with chronic airway disease. Here, we review the evolution of airway microbiology studies of chronic pulmonary disease, focusing on asthma, chronic obstructive pulmonary disease and cystic fibrosis. Building on evidence derived from traditional microbiological approaches and more recent culture-independent microbiome studies, we discuss the implications of recent findings on potential microbial determinants of respiratory health or disease.
直到最近,特定微生物物种的定植或感染证据与肺部疾病的发展、持续或恶化之间的关系,影响了我们对气道微生物组学的看法。然而,最近应用非培养工具进行微生物组分析,揭示了慢性肺部疾病患者气道中比以前认识到的更为多样化的微生物群。新的证据表明,在健康和疾病状态下,气道微生物组的组成是不同的,并且与症状的严重程度有关,而作为一个整体的微生物组可能有助于与慢性气道疾病相关的病理生理过程。在这里,我们回顾了慢性肺部疾病气道微生物组学研究的演变,重点关注哮喘、慢性阻塞性肺疾病和囊性纤维化。基于传统微生物学方法和最近的非培养微生物组研究获得的证据,我们讨论了最近的发现对呼吸道健康或疾病的潜在微生物决定因素的意义。